홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Trimetazidine

HCID 21109
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
5011-34-7
표준 SMILES
COc1ccc(CN2CCNCC2)c(OC)c1OC
InChIKey
UHWVSEOVJBQKBE-UHFFFAOYSA-N
분자식
C14H22N2O3
평균 분자량
266.34 g/mol
단동위원소 질량
266.16304257

개요

1-[(2,3,4-trimethoxyphenyl)methyl]piperazine is an aromatic amine.

이름 및 식별자

우선 이름
Trimetazidine
IUPAC
1-[(2,3,4-trimethoxyphenyl)methyl]piperazine
영어명
Trimetazidine
분자식
C14H22N2O3
분자량
266.34

이름 및 동의어

TRIMETAZIDINE5011-34-71-[(2,3,4-trimethoxyphenyl)methyl]piperazineTrimetazidinaTrimetazidinumDilatanN9A0A0R9S8Piperazine, 1-((2,3,4-trimethoxyphenyl)methyl)-DTXSID2048531Piperazine, 1-[(2,3,4-trimethoxyphenyl)methyl]-1-((2,3,4-trimethoxyphenyl)methyl)piperazineVastarel MR
이름 더 보기
TRIMETAZIDINE HCLVasorelVasartelAKOS B006602TIMTEC-BB SBB007020ART-CHEM-BB B006602ART-CHEM-BB B014361Trimetazidine USP/EP/BP
RefChem:191732DTXCID9027998C01EB15225-690-21-(2,3,4-Trimethoxybenzyl)piperazineMFCD008682631-(2,3,4-Trimethoxy-benzyl)-piperazinePreductal

데이터베이스 식별자

CAS
5011-34-7
PubChem CID
21109
DTXSID
DTXSID2048531
ChEMBL
CHEMBL203266
ChEBI
CHEBI:94789
UNII
N9A0A0R9S8
EC Number
225-690-2
Nikkaji
J8.797A

물성

구조 계산 물성

XLogP
1
극성 표면적
43 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
5
회전 가능 결합 수
5
무거운 원자 수
19
형식 전하
0
복잡도
259

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

Pharmaceuticals -> Listed in ZINC15

LogP1.04
Dissociation ConstantspKa1= 4.45 ± 0.02 and pKa2= 9.14 ± 0.02

물리화학적 성질

끓는 점
2 · bp2 200-205°
밀도
1.092 · 1.092±0.06 g/cm3(Predicted)
증기압
0.003 Pa · 0.003Pa at 25℃
저장 조건
Hygroscopic, Refrigerator, Under inert atmosphere
용해도
클로로프롬(약간 용해됨), 메탄올(약간 용해됨)
물리적 상태
고체
산도 계수 (pKa)
9.07 · 9.07±0.10(Predicted)
색상
무색 내지 담황색 젤
안정성
흡습성
LogP
1.143 at · 1.143 at 25℃ and pH6

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H226 (66.7%): Flammable liquid and vapor [Warning Flammable liquids]

P210, P233, P240, P241, P242, P243, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P301+P330+P331, P302+P352, P302+P361+P354, P303+P361+P353, P304+P340, P305+P351+P338, P305+P354+P338, P316, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P363, P370+P378, P403+P233, P403+P235, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory InformationREACH registered substance: Trimetazidine (EC: 225-690-2)
Hazard Classes and CategoriesFlam. Liq. 3 (66.7%)

독성 정보

Drug Induced Liver Injury · 4건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Trimetazidine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

안전 데이터

hazard_code
Xi
위험 등급
IRRITANT

화학 및 산업

약리 정보

ATC Code · 3건

C01EB15

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingTrimetazidine is 15% protein bound in plasma. Trimetazidine can bind to human serum albumin.
Pharmacodynamics · 1건

Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Patients should be counselled regarding the risk of use with reduced renal or hepatic function, worsening of extrapyramidal symptoms or other movement disorders, and risk of falls.

Mechanism of Action · 1건

During myocardial ischemia, anaerobic metabolism takes over, increasing levels of lactic acid. The decreased intracellular pH and increased concentration of protons activates sodium-hydrogen and sodium-calcium antiport systems, raising intracellular calcium concentrations, finally leading to decreased contractility. This injury to the myocardium raises concentrations of catecholamines, which activate hormone sensitive lipase, and increasing fatty acid concentrations in plasma. When the myocardium is repurfused, fatty acid oxidation becomes the dominant form of ATP production, maintaining an acidic pH, and further exacerbating the injury. The mechanism of action of trimetazidine is not fully understood. Trimetazidine may inhibit mitochondrial 3-ketoacyl coenzyme A thiolase, decreasing long chain fatty acid β-oxidation but not glycolysis in the myocardium. The decreased long chain fatty acid β-oxidation is compensated for by increased use of glucose, preventing a lowered myocardial pH, and further decreases in contractility. However, another study suggests that 3-ketoacyl coenzyme A thiolase may not be trimetazidine's target, and that this mechanism may be incorrect.

Biological Half-LifeIn young, healthy subjects, the half life of trimetazidine is 7.81 hours. In patients over 65, the half life increases to 11.7 hours.
Metabolism/Metabolites · 1건

Trimetazidine can be oxidized at the piperazine ring to form trimetazidine ketopiperazine. Trimetazidine can also be N-formylated, N-acetylated, or N-methylated at the piperazine ring to form N-formyltrimetazidine, N-acetyltrimetazidine, and N-methyltrimetazidine respectively. Alternatively, trimetazidine can be demethylated at the 2, 3, or 4 position of the 2,3,4-trimethoxybenzyl moiety to form 2-desmethyltrimetazidine, 3-desmethyltrimetazidine, or 4-desmethyltrimetazidine. The desmethyltrimetazidine metabolites can undergo sulfate conjugation or glucuronidation prior to elimination.

MeSH Pharmacological ClassificationDrugs used to cause dilation of the blood vessels.
Absorption, Distribution and Excretion · 4건

In elderly patients, a 35 mg oral modified release tablet reaches a mean Cmax of 115 µg/L, with a Tmax of 2.0-5.0 hours, and a mean AUC0-12 of 1104 h\*µg/L. In young, healthy patients, the same dose reaches a mean Cmax of 91.2 µg/L, with a Tmax of 2.0-6.0 hours, and an AUC0-12h 720 h\*µg/L.

Trimetazidine is 79-84% eliminated in the urine, with 60% as the unchanged parent compound. In a study of 4 healthy subjects, individual metabolites made up 0.01-1.4% of the dose recovered in urine. In the urine, 2-desmethyltrimetazidine made up 0-1.4% of the recovered dose, 3- and 4-desmethyltrimetazidine made up 0.039-0.071% each, N-methyltrimetazidine made up 0.015-0.11%, trimetazidine ketopiperazine made up 0.011-0.4%, N-formyltrimetazidine made up 0.035-0.42%, N-acetyltrimetazidine made up 0.016-0.19%, desmethyl trimetazidine O-sulphate made up 0.01-0.65%, and an unknown metabolite made up0.026-0.67%.

The volume of distribution of trimetazidine is 4.8 L/kg.

Trimetazidine clearance is strongly correlated with creatinine clearance. In eldery patients with a creatinine clearance of 72 ± 8 mL/min, trimetazidine clearance was 15.69 L/h. In young, healthy patients with a creatinine clearance of 134 ± 18 mL/min, trimetazidine clearance was 25.2 L/h.

상·하류 제품 정보

상류 원료

탄산나트륨(경회)1-Piperazinecarbaldehyde2,3,4-Trimethoxybenzyl chloride4-[(2,3,4-트리메톡시페닐)메틸]-1-피페라진카르복실산에틸에스테르1-클로로메틸-2,3,4-트리메톡시벤젠2,3,4-Trimethoxybenzaldehyde1-BOC-Piperazine

하류 제품

Lomerizine hydrochloride

관련 반응

14건
반응 기록 만들기
HRID 22261 반응식
HRID 22261반응물로
HRID 37177 반응식
HRID 37177반응물로
HRID 37178 반응식
HRID 37178반응물로
HRID 298576 반응식
HRID 298576반응물로
HRID 307602 반응식
HRID 307602반응물로
HRID 568735 반응식
HRID 568735반응물로
HRID 694702 반응식
HRID 694702반응물로
HRID 945736 반응식
HRID 945736반응물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트